The Centre approved Biological E’s Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
A health worker administers a dose of Covid-19 vaccine in New Delhi. (PTI Photo)
In a boost to India’s fight against coronavirus, the government gave nod to Biological E’s Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. The provision comes into effect from August 12.
Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India’s arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those above 18 yrs vaccinated with either Covishield or Covaxin, 6 months or 26 weeks after administration of 2nd dose. This provision would be live from 12th August.”
Further Strengthening India’s arsenal against COVID-19.@MoHFW_India approves Corbevax as #PrecautionDose for those above 18 yrs vaccinated with either Covishield or Covaxin, 6 months or 26 weeks after administration of 2nd dose.
This provision would be live from 12th August.
— Dr Mansukh Mandaviya (@mansukhmandviya) August 10, 2022
This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.
HERE’S ALL YOU NEED TO KNOW:
-The necessary changes in administration of heterologous precaution dose using Corbevax to those eligible and due for precaution dose have been made on the Co-WIN portal.
-This provision would be live from August 12.
-Corbevax will be available as precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for population above 18 years.
– There will be no change in existing guidelines for homologous precaution dose administration of Covaxin and Covishield,
-“This enables use of Corbevax as a heterologous Covid-19 vaccine for precaution dose administration in this age group,” Union Health Secretary Rajesh Bhushan said.
-The decision has been taken based on scientific evidence, global practices and the recommendations of domain knowledge experts.
-India’s Covid-19 vaccination program has achieved the historical milestone of administering more than 2 billion doses so far.
(With inputs from PTI)
— ENDS —